Generate Biomedicines pushes machine learning to create new protein drugs
Generate Biomedicines is using machine learning in the U.S. to design new protein drugs. Its pipeline includes candidates for severe asthma and CAR-T cell therapy.
AI Drug Discovery 1 article
Therapeutic discovery is the boundary for AI Drug Discovery. Coverage follows machine learning used for target identification, virtual screening, molecular generation, property prediction, medicinal chemistry and lead design, with attention to whether computational claims survive experimental validation. AI applied to diagnostics, basic biological modeling or workflow automation belongs elsewhere unless it directly changes how drug targets or candidate molecules are found, prioritized or optimized.